Navigation Links
Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business
Date:5/19/2009

LAVAL, QC, May 19 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) today reports its consolidated financial results for the fiscal year ended February 28, 2009. Neptune reports record revenues, EBITDA(1) and first-time profitability for the three-month period ended February 28, 2009. Neptune and Acasti Pharma amended their stock option plan.

Neptune reports consolidated operating results for its nutraceutical business and for its pharmaceutical subsidiaries Acasti Pharma Inc. and NeuroBioPharm Inc. Because its fiscal year changed to February 28 from May 31 and in order to make relevant comparisons, the Company compares the results of the three and nine-month period ended February 28, 2009 to the unaudited three and nine-month period of the previous fiscal year ended February 29, 2008.

    Financial Results: Three-Month Period ended February 28, 2009

    Sales Growth:
    -------------
    - Revenues for the three-month period ended February 28, 2009 totalled a
      record $3,772,000, a 31% increase compared to $2,875,000 for the three-
      month period ended February 29, 2008.

    Profitability Growth:
    ---------------------
    - EBITDA for the three-month period ended February 28, 2009 reached
      $888,000 which represents an increase of 155% compared to $348,000
      achieved during the three-month period ended February 29, 2008.

    Earnings Growth:
    ----------------
    - Net profit for the three-month period ended February 28, 2009 amounted
      to $71,000 or $0.002 per share, compared to a net loss of $886,000 or
      $0.024 per share, for the three-month period ended February 29, 2008.

    Financial Results: Nine-Month Period ended February 28, 2009

    Sales Growth:
    ------------
    - Revenues increased by 20.5% to $8,589,000, during the nine-month period
      ended February 28, 2009, from $7,129,000 achieved durin
'/>"/>
SOURCE  NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 

Related biology technology :

1. Neptune Product and Distribution Update
2. Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results
3. Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile
4. Acasti Pharma completes offer to exchange outstanding Neptune Technologies dividend notes
5. Neptune Technologies & Bioressources Inc. reports first quarter results
6. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
7. Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition
8. Neptune Krill Oil, NKO(R), enters WALGREENS, the largest U.S. retail pharmacy chain, under the brand name Schiff(R) MegaRed(TM)
9. Neptune Technologies decided not to re-price options
10. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
Post Your Comments:
*Name:
*Comment:
*Email: